- Roche Holdings AG’s RHHBY Cobas SARS-CoV-2 Test has received U.S. authorization for testing individuals without symptoms or reasons to suspect a COVID-19 infection.
- “The high-throughput, highly sensitive Cobas SARS-CoV-2 Test under FDA Emergency Use Authorization can now be used to test individual or pooled samples from people without symptoms or other reasons to suspect COVID-19,” Roche said in a statement.
- The test applies to pooled samples containing up to and including six individual samples.
- Price Action: RHHBY shares closed at $42.2 on Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
